FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Kiniksa Pharmaceuticals, Ltd. Stock AnalysisComprehensive stock analysis for Kiniksa Pharmaceuticals, Ltd. (KNSA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisKNSA
KNSA
Kiniksa Pharmaceuticals, Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
KNSA
Home🔹Stocks🔹Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd.

KNSA•NASDAQ

Kiniksa Pharmaceuticals, Ltd.

KNSA•NASDAQ
Market cap
$5.97B
Sentiment

Your view on KNSA

Mkt Cap
$5.97B
Sentiment
Your view
KNSA
Kiniksa Pharmaceuticals, Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
KNSA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Kiniksa Pharmaceuticals, Ltd.

Industry
Biotechnology
Sector
Healthcare
CEO
Sanj K. Patel
Headquarters
Clarendon House, Hamilton, BM
Industry
Biotechnology
Sector
Healthcare
CEO
Sanj K. Patel
Headquarters
Clarendon House, Hamilton, BM
Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News